Institute of Tropical Medicine Antwerp
Foundation of Public Utility

Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic

DSpace/Manakin Repository

Show simple item record Corbett, M. en_US Bogers, W. M. en_US Heeney, J. L. en_US Gerber, S. en_US Genin, C. en_US Didierlaurent, A. en_US Oostermeijer, H. en_US Dubbes, R. en_US Braskamp, G. en_US Lerondel, S. en_US Gomez, C. E. en_US Esteban, M. en_US Wagner, R. en_US Kondova, I. en_US Mooij, P. en_US Balla-Jhagjhoorsingh, S. en_US Beenhakker, N. en_US Koopman, G. en_US van der Burg, S. en_US Kraehenbuhl, J. P. en_US Le Pape, A. en_US 2008-05-15T15:51:24Z 2008-05-15T15:51:24Z 2008
dc.identifier.issn 0027-8424
dc.identifier.other ITG-M16B en_US
dc.identifier.other MICRO en_US
dc.identifier.other U-VIROL en_US
dc.identifier.other JIF en_US
dc.identifier.other DOI en_US
dc.identifier.other UPD2 en_US
dc.identifier.other ABSTRACT en_US
dc.description.abstract Each year, approximately five million people die worldwide from putatively vaccine-preventable mucosally transmitted diseases. With respect to mass vaccination campaigns, one strategy to cope with this formidable challenge is aerosol vaccine delivery, which offers potential safety, logistical, and cost-saving advantages over traditional vaccination routes. Additionally, aerosol vaccination may elicit pivotal mucosal immune responses that could contain or eliminate mucosally transmitted pathogens in a preventative or therapeutic vaccine context. In this current preclinical non-human primate investigation, we demonstrate the feasibility of aerosol vaccination with the recombinant poxvirus-based vaccine vectors NYVAC and MVA. Real-time in vivo scintigraphy experiments with radiolabeled, aerosol-administered NYVAC-C (Clade C, HIV-1 vaccine) and MVA-HPV vaccines revealed consistent mucosal delivery to the respiratory tract. Furthermore, aerosol delivery of the vaccines was safe, inducing no vaccine-associated pathology, in particular in the brain and lungs, and was immunogenic. Administration of a DNA-C/NYVAC-C prime/boost regime resulted in both systemic and anal-genital HIV-specific immune responses that were still detectable 5 months after immunization. Thus, aerosol vaccination with NYVAC and MVA vectored vaccines constitutes a tool for large-scale vaccine efforts against mucosally transmitted pathogens. en_US
dc.language English en_US
dc.publisher National Academy of Sciences en_US
dc.subject Vaccine administration en_US
dc.subject Aerosols en_US
dc.subject Safety en_US
dc.subject Feasibility en_US
dc.subject Efficacy en_US
dc.subject Disease transmission, mucosal en_US
dc.subject Primates en_US
dc.subject Clinical trials en_US
dc.title Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic en_US
dc.type Article en_US
dc.citation.issue 6 en_US
dc.citation.jtitle Proceedings of the National Academy of Sciences of the United States of America en_US
dc.citation.volume 105 en_US
dc.citation.pages 2046-2051 en_US Washington en_US
dc.citation.jabbreviation Proc Natl Acad Sci USA en_US

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record